Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SPL84-23

            Therapeutic Area: Genetic Disease Product Name: SPL84-23

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Biotel Limited

            Deal Size: $28.5 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing May 13, 2021

            Details:

            Proceeds will be used to advance the Company’s pipeline, including its lead Anti Sense Oligonucleotide product, SPL84-23. SPL84-23 to treat the 3849+10kb C->T CFTR mutation, that has showed ability to completely restore CFTR channel function in patient-derived cell cultures.